文献速递MDS 与骨髓增殖性肿瘤

什么是纤维化前骨髓纤维化以及2018年应如何管理

What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
PubMed 文献 · Br J Haematol · 2018-10-17

2016年世界卫生组织(WHO)将骨髓纤维化(MF)分为纤维化前(pre-MF)和明显MF两类,pre-MF这一新实体引发专家讨论。本文结合文献与真实病例综述其诊断、预后评分局限及管理策略,并提出管理建议。

要点

  • pre-MF诊断需骨髓活检,需权衡骨髓纤维化≥1级等特征。
  • pre-MF患者常为年轻成人,伴血小板增多和乳酸脱氢酶升高。
  • 现有预后评分系统对pre-MF有局限,总生存和进展风险信息有限。

核心结论

  • 本文综述pre-MF特征并提出管理策略,但总体生存和进展为明显MF或急性白血病的资料有限。

研究设计与样本

  • 临床聚焦的综述,结合当前已发表文献与真实病例讨论。

主要发现

  • 许多pre-MF患者为年轻成人,伴血小板增多、乳酸脱氢酶升高和骨髓纤维化≥1级。
  • 当前管理策略因年龄、合并症、骨髓特征和管理临床医生意见而异。
  • 预后评分系统对该实体有局限,pre-MF的总生存和进展为明显MF及急性白血病的信息有限。

关键数值与推荐

  • 2016年WHO分类将MF分为pre-MF和明显MF。
  • 诊断需骨髓环钻活检,并需解释及权衡其权重。

临床怎么用

  • 作者提出针对适用该诊断标签患者的管理策略。

局限性

  • 预后评分系统对该实体有局限。
  • 目前关于pre-MF的总生存和进展为明显MF及急性白血病的信息有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2016 World Health Organization (WHO) classification for myeloproliferative neoplasms (MPN) divided myelofibrosis (MF) into pre-fibrotic (pre-MF) and overt-MF categories. This new classification, particularly the entity pre-MF, has been a subject of discussion between experts. Important questions have been raised in recent years, such as the need for bone marrow trephine for diagnosis; how this is interpreted and the weighting given to it in assigning a diagnosis; determination of prognosis for pre-MF patients; including which scoring system to use and, ultimately, an evidence-based management plan for this group of patients. Many pre-MF patients present as young adults, with thrombocytosis, elevated lactate dehydrogenase levels and increased bone marrow fibrosis (i.e. ≥ grade 1). Current management strategies differ in view of age, comorbidities and bone marrow features and the opinion of the managing clinicians. Prognostic scoring systems have some limitations regarding this entity, and at the present time there is limited information about the overall survival and incidence of progression to overt-MF and acute leukaemia for pre-MF. In this clinically focussed article, we review the main characteristics of this new disease category in view of the current published literature and illustrate our discussion with some real patient cases. Lastly, we propose a management strategy for patients to whom this diagnostic label is applied.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Curto-Garcia N, Ianotto JC, Harrison CN, et al. What is pre-fibrotic myelofibrosis and how should it be managed in 2018? Br J Haematol. 2018. PMID: 30328618. doi:10.1111/bjh.15562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。